Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1111/j.1524-4733.2010.00724.x

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Aged, 80 and over; Breast Neoplasms /drug therapy /pathology; Chemotherapy, Adjuvant /economics; Cost-Benefit Analysis; Decision Support Techniques; Female; Gene Expression Profiling /economics; Genetic Testing /economics; Health Care Costs; Humans; Israel; Middle Aged; Quality-Adjusted Life Years; Recurrence; Reproducibility of Results; Risk Assessment; Survival Analysis

AccessionNumber
22010001332

Date bibliographic record published
24/11/2010